Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Palforzia

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

A healthy challenge

The EC’s Dr Vytenis Andriukaitis on Europe’s problems with health

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

- PMLiVE

Nestlé Health Science invests $145m in food allergy biotech

Aimmune Therapeutics' lead product is a phase III peanut allergy treatment

- PMLiVE

Merck licenses University of Edinburgh research tool

Gains access to novel disease progression technology

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

EISAI

Eisai wins EU licence for kidney cancer drug Kisplyx

Approved as a second-line combination treatment for advanced RCC

- PMLiVE

Lundbeck challenge to EC pay-for-delay ruling fails

Court upholds €94m fine for paying off firms to delay launch of Celexa generics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links